By submitting this form, you are agreeing to the Terms of Use and Privacy Policy.
A nasal cannula is a medical device that helps persons with low oxygen levels receive additional oxygen therapy. Nasal cannulas come in two varieties: low flow and high flow. The two-pronged gadget rests beneath the nose. Your nose receive oxygen directly from the two prongs.
Using a nasal cannula has hazards that include:Abdominal constriction Abdominal distension, or stomach bloating, is particularly dangerous for young children and those who are under anaesthesia.
Other oxygen delivery systems maintain a higher degree of positive end-expiratory pressure and pose no distension risk.
A reduced positive airway pressure in HFNCs, however, may allow some gas to enter the digestive system and result in abdominal bloating.Nasal irritation or damage. Although it can happen with high flow systems as well, this is more typical with low flow nasal cannulas.
Global nasal cannula oxygen therapy devices market accounted for $XX Billion in 2023 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.
Release of High-Flow Oxygen Therapy Device by Nocca Robotics Noccarc H210 for the treatment of COVID-19 patients requiring critical care.
Nocca Robotics Pvt Ltd, an incubator firm of SIIC, IIT Kanpur, which offers clinically validated, accredited, and high-quality critical care equipment, has introduced a High-Flow Oxygen Therapy Device in an effort to aid COVID-19 patients.
The state-of-the-art tool is simple to use and pleasant for the patients, and it has been shown to be successful in the treatment of COVID-19 patients. The likelihood of intubation is dramatically decreased by high-flow oxygen therapy.
The present pandemic and the increasing number of COVID-19 patients address the urgent need for high flow oxygen therapy devices in the nation, which is addressed by the Noccarc H210.
Oral suctioning and expectoration are made simple by high-flow oxygen therapy. The enhanced epithelial muco-ciliary caused by the heated and humidified gas also reduces the incidence of respiratory problems including pneumonia and delirium.
The patient’s ability to speak with the medical staff is facilitated by the use of a cannula in HFOT, which also lowers the patient’s chance of developing tomophobia as a result of intubation.
Masimo has announced the launch of softFlow High-Flow Nasal Cannula Therapy in the United States. Through a soft nasal cannula, the technology, which is included with the softFlow 50, provides adult patients with high-flow respiratory assistance by producing a steady high flow of warm, humidified air or an air/oxygen mixture.
SoftFlow gives doctors working across the continuum of care an essential tool to aid in the care of patients who are breathing on their own as the COVID-19 epidemic spreads and causes an increase in the number of patients needing respiratory support.
SoftFlow was built for maximum adaptability, making it useful in a variety of settings including the home, long-term care homes, and hospitals.
It can operate without an external compressed air source.SoftFlow employs a single-patient flow path from the internal mixing chamber to the patient as well as a bacterial/viral filter made to remove impurities from the air provided to the patient in order to lower the chance of cross-contamination.
Both the U.S. National Institutes of Health (NIH) and the World Health Organisation (WHO) have recommended that the use of High-Flow Nasal Cannula (HFNC) therapy, such as softFlow, is a viable option for providing respiratory support for a subset of COVID-19 patients for whom traditional oxygen therapy may not be adequate.
Compared to traditional oxygen therapy, softFlow can deliver higher oxygen flow rates to individuals with COVID-19 or other respiratory diseases
.In terms of treatment, the NIH came to the conclusion that “HFNC is preferred over Noninvasive Positive Pressure Ventilation (NIPPV) in patients with acute hypoxemic respiratory failure based on data from an unblinded clinical trial in patients without COVID-19 who had acute hypoxemic respiratory failure.”
According to the cited study, HFNC resulted in more days without a ventilator (24 days) than either NIPPV (19 days) or standard oxygen therapy (22 days) (p=0.02). Additionally, compared to NIPPV or traditional oxygen therapy, the researchers discovered a decreased 90-day mortality rate.
It is challenging for patients to eat, drink, and speak while using mask-based forms of respiratory assistance, but with softFlow, the airflow is continually given through the nose.
The softFlow 50 system also delivers warm, humidified gas directly into the patient’s nose to improve comfort and facilitate mucus clearing.
Clinicians can take use of the high-flow rate to assist reduce the entrainment of room air thanks to its capacity to precisely administer high respiratory gas flow rates substantially above those needed for usual respiratory demand. This fact makes [usage as] a therapy for people who are hypercapnic possible.
The device’s ability to prevent condensation in the applicator by warming the entire tube system up to the nasal cannula is another very advantageous feature. Overall, they are pleased with the way the device was handled and the clinical outcomes.
